Pharmacogenomic approaches in antidiabetic drug development

Drug Development Research

Volumn 62, Issue 3, 2004, Pages 207-212

  Rosmond, Roland ^a  

^a NONE   (Sweden)

Author keywords

Antidiabetic drugs; Diabetes; Drug development; Genes; Pharmacogenomics

Indexed keywords

ANTIDIABETIC AGENT;

AMINO ACID SEQUENCE; DIABETES MELLITUS; DISEASE COURSE; DNA MICROARRAY; DNA SEQUENCE; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; PHARMACODYNAMICS; PHARMACOGENOMICS; PHENOTYPIC VARIATION; PROTEIN LOCALIZATION; REVIEW; TREATMENT OUTCOME;

EID: 10044280433     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10358     Document Type: Review

References (14)

1. Benet LZ, Mitchell JR, Sheiner LB. 1990. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, editors. Goodman and Gilman's the pharmacological basis of therapeutics. New York: Pergamon Press, p 3-32.
2. Cerasi E, Luft R. 1967. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol (Copenh) 55:330-345.
3. Drazen JM, Yandava CN, Dube L, Szerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, and others. 1999. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 22:168-170.
4. Judson R, Stephens JC. 2001. Notes from the SNP vs. haplotype front. Pharmacogenomics 2:7-10.
5. Marton MJ, DeRisi JL, Bennett HA, Iyer VR, Meyer MR, Roberts CJ, Stoughton R, Burchard J, Slade D, Dai H, and others. 1998. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 4: 1293-1301.
6. Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamami LC, Boehni MF, Mondon CE, Nadzan AM, and others. 1997. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 386:407-410.
7. Roden DM. 2003. Cardiovascular pharmacogenomics. Circulation 108:3071-3074.
8. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, and others. 2001. A map of human genome sequence variation containing 1.42 million single nucleoticle polymorphisms. Nature
9. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL Jr, Goldstein SA. 2000. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 97:10613-10618.
10. Stephens JC, Schneider JA, Tanguay DA, Choi J, Achaiya T, Stanley SE, Jiang R, Messer CJ, Chew A, Hau JH, and others. 2001. Haplotype variation and linkage disequilibrium in 313 human genes. Science 293:489-493.
11. Tsai YJ. Hoyme HE. 2002. Phamacogenomics: the future of drug therapy. Clin Genet 62:257-264.
12. Vesell ES, Page JG. 1968. Genetic control of drug levels in man: antipyrine. Science 161:72-73.
13. Watters JW, McLeod HL. 2003. Using genome-wide mapping in the mouse to identify genes that influence drug response. Trends Pharmacol Sci 24:55-58.
14. Zhao Z, Fu YX, Hewett-Emmett D, Boeradnkle E. 2003. Investigating single nucleotide polymorphism (SNP) density in the human genome and its implications for molecular evolution. Gene 312:207-213.